Prothrombin G20210A (Factor II) Mutation Detection, EDTA Blood

The Prothrombin G20210A mutation is found in the FII gene in the body. This mutation affects blood clotting by increasing the levels of prothrombin, a protein involved in forming clots, and increases the risk of developing blood clots. Understanding this mutation helps in assessing the risk of venous thrombosis and informing appropriate treatment decisions. The Prothrombin G20210A (Factor II) Mutation assay is used to detect the G20210A mutation in the FII gene. This mutation is associated with an increased risk of venous thrombosis, which is the formation of blood clots in the veins. The clinical utility of this assay lies in identifying individuals who may be at higher risk for developing venous thrombosis. It is particularly beneficial for individuals with a personal history of venous thrombosis, those with a family history of the condition, and pregnant women or women taking oral contraceptives who have previously experienced a venous thrombotic event. By identifying individuals with this mutation, appropriate preventive measures and management strategies can be implemented to reduce the risk of future thrombotic events.